Cargando…

PB2192: JAK2 V617F ALLELE BURDEN AND THROMBOTIC EVENTS IN PATIENTS WITH JAK2 V617F POSITIVE POLYCYTHEMIA VERA OR ESSENTIAL THROMBOCYTHEMIA AT HIGH RISK OF THROMBOSIS

Detalles Bibliográficos
Autores principales:	Hwang, Yun Hui, Bae, Sung Hwa, Lee, A-Jin, Kim, Min Kyoung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428696/ http://dx.doi.org/10.1097/01.HS9.0000975520.02908.5e

Ejemplares similares

Clinical features and outcomes of JAK2 V617F-positive polycythemia vera and essential thrombocythemia according to the JAK2 V617F allele burden
por: Lee, A-Jin, et al.
Publicado: (2021)

PB2178: EVALUATION OF JAK2 EXON 12 MUTATIONS IN PATIENTS WITH JAK2 (V617F)-NEGATIVE POLYCYTHEMIA VERA
por: Khosravi, Sahar, et al.
Publicado: (2023)

JAK2(V617F) allele burden in polycythemia vera: burden of proof
por: Moliterno, Alison R., et al.
Publicado: (2023)

Sigmoid Venous Thrombosis in JAK2 V617F Mutated Polycythemia Vera
por: Martins De Oliveira Filho, Cilomar, et al.
Publicado: (2022)

JAK2 V617F and the evolving paradigm of polycythemia vera
por: Means, Robert T.
Publicado: (2010)

Distinguishing essential thrombocythemia JAK2V617F from polycythemia vera: limitations of erythrocyte values
por: Silver, Richard T., et al.
Publicado: (2019)

Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET)
por: Zhao, Shixiang, et al.
Publicado: (2016)

Cerebral venous sinus thrombosis in polycythemia vera patients with JAK2V617F mutation
por: Shen, Hui-Xin, et al.
Publicado: (2021)

Iron deficiency in JAK2 exon12 and JAK2-V617F mutated polycythemia vera
por: Liu, Dan, et al.
Publicado: (2021)

JAK2 V617F polycythemia vera and essential thrombocythemia: dynamic clinical features associated with long-term outcomes
por: Sureau, Léa, et al.
Publicado: (2022)

JAK2 V617F-positive polycythemia vera accompanied by renal artery stenosis
por: Kim, Jae Young, et al.
Publicado: (2014)

JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis
por: Guglielmelli, Paola, et al.
Publicado: (2021)

PB2250: THE IMPACT OF JAK2V617F MUTATION POSITIVITY IN ESSENTIAL THROMBOCYTHEMIA:ABOUT 74 CASES.
por: Cheffai, Arij, et al.
Publicado: (2023)

Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study
por: Vannucchi, Alessandro Maria, et al.
Publicado: (2017)

Changes in peripheral blood lymphocytes in polycythemia vera and essential thrombocythemia patients treated with pegylated-interferon alpha and correlation with JAK2(V617F) allelic burden
por: Kovacsovics-Bankowski, Magdalena, et al.
Publicado: (2016)

Chorea Associated with JAK2(V617F) ‐Positive Essential Thrombocythemia
por: Calculli, Alessandra, et al.
Publicado: (2022)

Absence of JAK2 V617F-mutated polycythemia vera in obstructive sleep apnea-associated erythrocytosis
por: Langabeer, Stephen E.
Publicado: (2022)

JAK2 p.V617F Variants in Non-Blood DNA from Patients with Polycythemia Vera
por: Mori, Naoki, et al.
Publicado: (2023)

Influence of JAK2V617F allele burden on clinical phenotype of polycythemia vera patients: A study from India
por: Sazawal, Sudha, et al.
Publicado: (2019)

JAK2V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome
por: Kanduła, Zuzanna, et al.
Publicado: (2022)

Combination therapy with interferon and JAK1-2 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera
por: Bjørn, M.E., et al.
Publicado: (2014)

Chronic urticaria reveals JAK2V617F positive essential thrombocythemia
por: Albanesi, Marcello, et al.
Publicado: (2021)

PB2040: INTERRELATION BETWEEN JAK2 V617F MUTATION AND THE INCIDENCE OF THROMBOTIC EVENTS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS
por: Nikolova, D., et al.
Publicado: (2022)

Emergence of BCR-ABL1 Chronic Myeloid Leukemia in a JAK2-V617F Polycythemia Vera
por: Lorenzo, Mariana, et al.
Publicado: (2020)

Cerebral Venous Sinus Thrombosis as the First Manifestation of JAK2(V617F)-positive Essential Thrombocythemia
por: Chen, Wei-Bi, et al.
Publicado: (2018)

Molecular Pathogenesis and Therapy of Polycythemia Induced in Mice by JAK2 V617F
por: Zaleskas, Virginia M., et al.
Publicado: (2006)

Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo
por: Verger, Emmanuelle, et al.
Publicado: (2018)

Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera
por: Lussana, Federico, et al.
Publicado: (2017)

Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms
por: Yonal-Hindilerden, Ipek, et al.
Publicado: (2015)

Thrombopoietin is required for full phenotype expression in a JAK2(V617F) transgenic mouse model of polycythemia vera
por: Spivak, Jerry L., et al.
Publicado: (2020)

Association of polycythemia vera with positive JAK2V617F mutation and myasthenia gravis: A report of two cases
por: Sasi, Sreethish, et al.
Publicado: (2020)

JAK2V617F Allele Burden Measurement in Peripheral Blood of Iranian Patients with Myeloproliferative Neoplasms and Effect of Hydroxyurea on JAK2V617F Allele Burden
por: Ferdowsi, Shirin, et al.
Publicado: (2016)

Vitamin D Deficiency and Janus kinase 2 V617F Mutation Status in Essential Thrombocythemia and Polycythemia Vera
por: Yikilmaz, Aysun Şentürk, et al.
Publicado: (2020)

Genetic Knock-out of TNFR1 and TNFR2 in a JAK2-V617F Polycythemia Vera Mouse Model
por: Müller, Peter, et al.
Publicado: (2022)

JAK2V617F-Positive Endothelial Cells Induce Apoptosis and Release JAK2V617F-Positive Microparticles
por: Hekimoğlu, Hilal, et al.
Publicado: (2022)

Absence of JAK2V617F Mutated Endothelial Colony-Forming Cells in Patients With JAK2V617F Myeloproliferative Neoplasms and Splanchnic Vein Thrombosis
por: Guy, Alexandre, et al.
Publicado: (2020)

Oral squamous cell carcinoma with essential thrombocythemia and positive JAK2 (V617F) mutation
por: Rahman, Kurnia H., et al.
Publicado: (2021)

Hematological relevance of JAK2 V617F and calreticulin mutations in Tunisian patients with essential thrombocythemia
por: Abdelghani, Maroua, et al.
Publicado: (2022)

Pronounced gut microbiota signatures in patients with JAK2V617F-positive essential thrombocythemia
por: Eickhardt-Dalbøge, Christina Schjellerup, et al.
Publicado: (2023)

Case report: Double L611S/V617L JAK2 mutation in a patient with polycythemia vera originally diagnosed with essential thrombocythemia
por: Li, Xiao-qing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vn904880ikovc2apcq97tl713t